7月13日 - ** 生物技术公司Niagen Bioscience（NAGE.O）的股价在盘前交易中上涨2.6%，至3.47美元
** 该公司表示，其试验性药物NB4168已获得美国和欧洲针对共济失调-毛细血管扩张症的罕见病认定，该病是一种罕见的遗传性疾病，会影响运动功能、削弱免疫系统并增加患癌风险
** 公司表示，这些认定提供了监管激励措施，有助于支持罕见病治疗药物的研发，并强化了在全球推进NB4168研发的计划
** 公司表示，目前尚无针对该疾病的获批疗法
** NAGE表示，该药物正处于临床前研发阶段，并计划申请美国食品药品监督管理局（FDA）批准以启动人体试验
** 截至上一交易日收盘，NAGE今年以来累计下跌46.7%
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.